Hepatitis C virus promotes Th17 responses through TSLP production by infected hepatocytes

Hepatitis C virus (HCV) is a major cause of liver cirrhosis and hepatocellular carcinoma. Here, we report that infection of hepatic cells by HCV stimulates NFκB-dependent production of thymic stromal lymphopoietin (TSLP). Hepatocyte-derived TSLP in turn conditions DCs to drive Th17 differentiation....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hepatology (Baltimore, Md.) Md.), 2013-03, Vol.57 (4), p.1314-1324
Hauptverfasser: Lee, Hai-Chon, Sung, Sung-Sang J., Krueger, Peter D., Jo, Yoon-Ah, Rosen, Hugo R., Ziegler, Steven F., Hahn, Young S.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Hepatitis C virus (HCV) is a major cause of liver cirrhosis and hepatocellular carcinoma. Here, we report that infection of hepatic cells by HCV stimulates NFκB-dependent production of thymic stromal lymphopoietin (TSLP). Hepatocyte-derived TSLP in turn conditions DCs to drive Th17 differentiation. The TSLP secreted by HCV-infected hepatoma cells is capable of activating human monocyte-derived DCs by upregulating the expression of CD40, CD86, CCL17, CCL22, and CCL20 which is activating marker of DCs. In addition, the production of key cytokines for Th17 differentiation, TGF-β, IL-6 and IL-21, is enhanced by human monocytes upon co-culture with HCV-infected cells. Importantly, the blockade of TSLP using neutralizing antibody prevented the activation and maturation of DCs as well as the production of Th17 differentiation cytokines. DCs conditioning by TSLP secreted from HCV-infected cells activated naïve CD4 + T lymphocytes, resulting in Th17 differentiation. Furthermore, we can detect substantial levels of hepatocyte TSLP in fibrotic liver tissue from chronic HCV patients. Thus, blockade of TSLP released by HCV-infected hepatocytes may suppress the induction/maintenance of hepatic Th17 responses and halt the progression of chronic liver disease to fibrosis and liver failure.
ISSN:0270-9139
1527-3350
DOI:10.1002/hep.26128